[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Radiometer Medical ApS\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":90},{"warningLetters":4,"total":89},[5,31,51,71],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1030,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-03-11T04:00:00Z\">03\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-05T05:00:00Z\">02\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fqapel-medical-inc-699244-02052025\">Q’Apel Medical, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jodie C. Fam\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Q’Apel Medical, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4245 Technology Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fremont\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94538\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 5, 2025\u003C\u002Fp>\u003Cp>Dear Ms. Fam:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Fremont, CA on July 29, 2024, through August 8, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the 072 Aspiration System (also marketed under the trade name “HIPPO”). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>FDA has reviewed information collected during the inspection of your firm located in Fremont, California on July 29, 2024, through August 8, 2024, and determined that the 072 Aspiration System (HIPPO) is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. §351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the device as described and marketed. The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C.\u003C\u002Fp>\u003Cp>Specifically, FDA cleared, under K222786, the device that you identified in your submission to the agency as the 072 Aspiration System with the following indications, “072 Aspiration Catheter: As part of the 072 Aspiration System, the 072 Aspiration Catheter with a compatible suction pump is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral - M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who failed IV t-PA therapy are candidates for treatment. Aspiration Tubing: As part of the 072 Aspiration System, the Aspiration Tubing is intended to connect the 072 Aspiration Catheter to a compatible suction pump.” The 072 Aspiration System that was presented to us was cleared under K222786 with a design that included a catheter shaft with an inner diameter of 0.072 inch and an outer diameter of 0.0855 inch for the entire catheter working length. The submission that we numbered K222786 did not describe technological characteristics of the distal nitinol tip that would enable expansion of the distal tip to larger diameters or compression of the distal tip during clinical use. However, your firm’s promotion of the device and information collected during the inspection provides evidence that the device as it was designed and developed but not described in your submission includes a nitinol tip with technological characteristics that allow for expansion in diameter and compression in length, i.e., a device for which your firm lacks clearance or approval. Examples of the promotion and information include:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> data report of tip compression testing (“Hippo Tip Vacuum Ball Testing”) was shared via emails exchanged within Q’Apel Medical \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The data include tip diameter and length measurements of multiple catheter tips (“bad units” and “good units”) while vacuum was applied to a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ball with a diameter larger than the HIPPO distal tip diameter. Multiple images show increased diameters of the distal region of the nitinol tip expanding around the surface of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> ball with reported increases in diameters of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for “good units” and increases in diameter of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for “bad units.” The \u003Cstrong>(b)(4)\u003C\u002Fstrong> data reports tip diameters ranging from \u003Cstrong>(b)(4)\u003C\u002Fstrong> inch with aspiration applied to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> ball, compared to the relaxed tip diameter of \u003Cstrong>(b)(4)\u003C\u002Fstrong> inch to \u003Cstrong>(b)(4)\u003C\u002Fstrong> inch. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> data reports accompanying changes in tip length of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (relaxed tip lengths of \u003Cstrong>(b)(4)\u003C\u002Fstrong> inch, compressed under ball aspiration to lengths of \u003Cstrong>(b)(4)\u003C\u002Fstrong> inch) for “good units” and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (relaxed tip lengths of \u003Cstrong>(b)(4)\u003C\u002Fstrong> inch, compressed under ball aspiration to lengths of \u003Cstrong>(b)(4)\u003C\u002Fstrong> inch) for “bad units.” The distinction of “good units” and “bad units” is not described in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> data. However, both “good units” and “bad units” describe evidence of increased HIPPO distal tip diameters and compressed tip lengths when aspiration was applied to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> balls. The submission K222786 did not provide images or information to show expansion of the distal tantalum markers or compression of tip length of the nitinol tip as shown in the images included in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> data of tip compression testing (“Hippo Tip Vacuum Ball Testing”).\u003C\u002Fli>\u003Cli>The “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” includes a video on page 35 of 45 titled “Mechanism of action,” that shows the nitinol tip of the HIPPO catheter aspirating a simulated clot. The video shows the catheter tip compress near the mid-point of the nitinol tip structure (with possible increased diameter), while the distal tantalum petal markers are obscured by the simulated clot. A second distinct slow-motion video also titled, “Mechanism of action,” is included on page 36 of 45 of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” that shows the nitinol tip of the HIPPO catheter aspirating a simulated clot. This video shows the HIPPO catheter tip prior to contact with the simulated clot and upon contact with the simulated clot, the distal tantalum petal markers on the most distal struts of the nitinol tip are shown to flare at the edges combined with longitudinal compression of the nitinol tip while aspiration is applied to the clot until the clot is fully ingested through the catheter lumen. Page 37 of 45 of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” includes a slow-motion video titled, “Mechanism of action: RED 72,” that shows aspiration of simulated clot with the cleared RED 72 Reperfusion Catheter (K211654) that was cited as a reference device during review of K222786 for the 072 Aspiration System (HIPPO). The video of the RED 72 Reperfusion Catheter does not show compression of the catheter tip or expansion of the distal catheter tip as observed in the videos of the HIPPO device on pages 35 and 36 of 45 of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Page 45 of 45 of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” also includes a claim that the HIPPO provides “insightful navigation from a tip that flexes to any clot morphology.” The submission K222786 of the 072 Aspiration System (HIPPO) did not provide images that showed compression of the nitinol tip nor flaring of the distal petals of the nitinol tip as shown in videos presented in the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003Cbr>• Drawing CS00788, “072 Catheter Nitinol Tip,” descriptions in the “Design History” notes that revision E updates included, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” The version of the drawing provided in K222786\u002FS001, Appendix 27, was revision D and did not include descriptions of \u003Cstrong>(b)(4)\u003C\u002Fstrong> specification changes or “\u003Cstrong>(b)(4)\u003C\u002Fstrong> compression testing with tip compression tool.” The “\u003Cstrong>(b)(4)\u003C\u002Fstrong>, CS 00788 Catheter Nitinol Tip,” document number QI 01560 describes \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The images and test methods for compression of the nitinol tip were not described in drawing CS00788, revision D, provided in K222786. The submission K222786 otherwise did not provide images that showed compression of the nitinol tip as described in document QI 01560.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During review of K222786, FDA asked for a description of the principle of operation and mechanism of action of the 072 Aspiration Catheter distal tip, including the tip dimensions related to the dimensions of the remainder of the catheter shaft, in the Refuse-to-Accept (RTA) notification dated September 30, 2022. The response provided in the document “002_Cover Letter_RTA_Final.pdf” of the K222786\u002FS001 submission dated October 24, 2022, stated that the 072 Aspiration Catheter tip had “\u003Cem>the same Internal (0.072”) and External (0.0855”) dimensions (ID, OD) as the rest of the catheter’s usable length. The length of the tip is \u003Cstrong>(b)(4)\u003C\u002Fstrong>”. The flexible tip is a passive structure that does not have an active mechanism of action and is not self-expanding\u003C\u002Fem>.” The information gathered in the inspection conducted July 29, 2024, through August 8, 2024, at your firm raises concerns that the information provided to FDA for review in K222786 did not accurately disclose the technological characteristics of the nitinol tip and the changes in diameter and length of the distal tip that could be exhibited during use conditions for aspiration of thrombus from patients experiencing acute ischemic stroke. These different technological characteristics of the nitinol tip to change in length and diameter constitute a change or modification in the device that could significantly affect the safety or effectiveness of the device (e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process) (21 CFR 807.81(a)(3)).\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the FDA. See 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Our office requests that Q’Apel Medical cease any activities that result in the misbranding or adulteration of the 072 Aspiration System (HIPPO), such as the commercial distribution of the device for the uses discussed above.\u003C\u002Fp>\u003Cp>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received response from Jim Talbot, Vice President Regulatory, Quality, and Clinical Affairs dated August 28, 2024, September 26, 2024, and November 27, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately document design input requirements as required by 21 CFR 820.30(c).\u003C\u002Fp>\u003Cp>For example, your firm did not adequately define the physical, performance, and other design requirements for design inputs to include tip compression, aspiration\u002Fsuction pump, tip deflection, and treatment location for your firm’s 072 Aspiration System (Hippo), which are identified in your documents titled, Product Specification 072 Aspiration System (PS 00922, Rev. G) and Customer Requirement Specification Form (CRS 00848, Rev. D).\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm has not adequately defined specifications for tip elongation and compression (PS-11.5.2), aspiration flow rate (PS-11.5.3) and tip deflection (PS-11.5.9) that are identified in your document titled, Product Specification, PS 00922, Revision H.\u003C\u002Fp>\u003Cp>Your firm provided the document titled, Draft Research Report, Aspiration System, Aspiration Flowrate Acceptance Criteria, RR 02139, in your response dated August 28, 2024. This document appears to leverage previous testing of the Aspiration flowrate to define measurable acceptance criteria for future Aspiration Flowrate testing. The comparative device testing was conducted on a sample size of three \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The conclusion states an acceptance interval for the average flow rate is \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This value was not reflected in your Product Specification documentation or the Test Protocol, TP 00927, which is to be executed for future verification testing by a third-party service provider. It is not clear what this data will be used for.\u003C\u002Fp>\u003Cp>Please evaluate the adequacy of your corrective actions related to design inputs and continue to provide us information related to your ongoing corrective actions.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures for design verification as required by 21 CFR 820.30(f).\u003C\u002Fp>\u003Cp>For example, your firm did not adequately define acceptance criteria that can be verified for Aspiration Flowrate, Tip Deflection, and Tip Compression and Elongation in your protocol titled, Test Protocol, Device Performance Design Verification Validation, FG 00806, FG 00995 (TP 00927, Rev. C).\u003C\u002Fp>\u003Cp>Additionally, the verification test performed for Aspiration Flowrate and documented in Test Report 072 Aspiration System, Design Verification Validation, FG00806, FG 00995, Aspiration Flowrate (TR 00927-15, Rev. A), was conducted using \u003Cstrong>(b)(4)\u003C\u002Fstrong> vacuum setting, whereas the Instructions for Use for the device describes \u003Cstrong>(b)(4)\u003C\u002Fstrong> vacuum settings the device can be used with. There is no documented rationale to justify why testing flowrate at \u003Cstrong>(b)(4)\u003C\u002Fstrong> setting is adequate.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm still has not implemented your design control procedure, in that your design verification protocol continues to not establish acceptance criteria for specifications to include tip deflection, elongation and compression, and aspiration flow rate that can be verified. Additionally, your firm’s rationale for testing a \u003Cstrong>(b)(4)\u003C\u002Fstrong> vacuum pressure is inadequate. Verification testing should be performed for all \u003Cstrong>(b)(4)\u003C\u002Fstrong> ranges utilized by the device.\u003C\u002Fp>\u003Cp>Your firm stated that you are \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, the Test Report has not been provided to FDA.\u003C\u002Fp>\u003Cp>Please evaluate the adequacy of your corrective actions related to design verification and continue to provide us information related to your ongoing corrective actions.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish and maintain procedures for design change as required by 21 CFR 820.30(i).\u003C\u002Fp>\u003Cp>For example, your firm has not implemented your procedure for design changes titled, Design Control (SOP 00003, Rev. C, effective date 02\u002F01\u002F2021 &amp; Rev. D, effective date 11\u002F14\u002F2022) (revisions in effect when design changes were processed), which states that design changes are subject to original verification or validation tests and if no test(s) or a subset is planned, a justification is required. Specifically, your firm has not evaluated the impact changes may have to original verification or validation tests or provided a justification if no test(s) or a subset is required. Design changes were made to update the specification for your 072 Cather, Nitinol Tip \u003Cstrong>(b)(4)\u003C\u002Fstrong> (under ECO 1142) and to update the \u003Cstrong>(b)(4)\u003C\u002Fstrong> specification (under ECO 1360) \u003Cstrong>(b)(4)\u003C\u002Fstrong> acceptability range \u003Cstrong>(b)(4)\u003C\u002Fstrong>. No assessment was documented of the potential impact the changes could have on completed verification and\u002For validation tests.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s reevaluation of ECO 1360 states that the firm’s risk management document, RM 00951, Design FMEA, 072 Aspiration System, was updated in ECO 1300 to capture the new risk identified with SA 00570 \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It further states that testing was performed via \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm determined that verification and\u002For validation testing was not required. This assessment is inadequate. Testing should be documented and performed according to a defined protocol.\u003C\u002Fp>\u003Cp>Please evaluate the adequacy of your corrective actions related to design changes and continue to provide us information related to your ongoing corrective actions.\u003C\u002Fp>\u003Cp>4. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>For example, your firm has not adequately implemented your complaint procedure, Complaint Handling and Customer Feedback (SOP 00148, Rev. M, effective date 02\u002F27\u002F2024), which requires returned product analysis to be completed within 30 days after receiving the product from the field. Specifically,\u003C\u002Fp>\u003Cul>\u003Cli>CN 0251 was opened to document a complaint reporting resistance was felt while the Hippo 072 Aspiration Catheter was inside an access catheter. The associated complaint product was received by your firm on 06\u002F12\u002F2024 under RMA0494 and logged in RMA log. As of 08\u002F02\u002F2024 the complaint product has not been investigated.\u003C\u002Fli>\u003Cli>CN 0252 was opened to document a complaint reporting stretching on the distal portion of the 072 Aspiration Tubing. The associated complaint product was received by your firm on 06\u002F27\u002F2024 under RMA0493 and logged in RMA log. As of 08\u002F02\u002F2024 the complaint product has not been investigated.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Removing the 30-day timeframe for completing the returned product analysis may impact your firm’s assessment of complaints that are determined to be malfunctions and thus your firm’s adherence to reporting timeframes required as part of the Medical Device Reporting (MDR) Regulation (see 21 CFR Part 803). Your firm should provide a risk-based justification for the removal of the requirement and evaluate complaints to determine if any unreported MDRs were found.\u003C\u002Fp>\u003Cp>5. Failure to adequately establish and maintain procedures for document control as required by 21 CFR 820.40.\u003C\u002Fp>\u003Cp>For example, your firm did not adequately implement your document control procedures as outlined in \u003Cstrong>(b)(4)\u003C\u002Fstrong> (SOP 00002, Rev. R, effective date 05\u002F24\u002F2024 (current revision), Rev. P, effective date 02\u002F02\u002F2024, and Rev. N, effective date 07\u002F14\u002F2023. Section 6.1 of your procedure titled \u003Cstrong>(b)(4)\u003C\u002Fstrong> (SOP 00460, Rev, A, effective date 9\u002F14\u002F2020) \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Specifically, the following promotional material for the 072 Aspiration System (Hippo) was not developed and approved per the firm’s document control procedures:\u003C\u002Fp>\u003Cul>\u003Cli>A video clip depicting the tip of the Hippo aspiration catheter flaring out\u003C\u002Fli>\u003Cli>A video clip referring the to the Hippo aspiration catheter tip as adaptive, depicting the tip of the Hippo aspiration catheter flaring out, and referencing R&amp;D Aspiration Grip Force data\u003C\u002Fli>\u003Cli>A press release announcing the clearance of the Hippo 072 Aspiration System that describes the aspiration tip as adaptive\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We reviewed your firm’s response and cannot determine the adequacy at this time. Your firm extended the target completion date to 11\u002F25\u002F2025, for compiling of a list of marketing\u002F promotional content for their Armadillo and Walrus devices and evaluating if product claims were found. \u003Cstrong>(b)(4)\u003C\u002Fstrong>; therefore, we request that you continue to provide information related to the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via e-mail to: Jessica Mu, Assistant Director at CDRHWarningLetterResponses@fda.hhs.gov. Refer to the Unique Identification Number, \u003Cstrong>CMS # 699244\u003C\u002Fstrong>, when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov or 619-941-3763.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Sean M. Boyd, MPH, USPHS\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJodie C. Fam\n\nRecipient Title\n\nChief Executive Officer\n\nQ’Apel Medical, Inc.\n\n4245 Technology Drive\n\nFremont, CA 94538\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nFebruary 5, 2025\nDear Ms. Fam:\nDuring an inspection of your firm located in Fremont, CA on July 29, 2024, through August 8, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the 072 Aspiration System (also marketed under the trade name “HIPPO”). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nFDA has reviewed information collected during the inspection of your firm located in Fremont, California on July 29, 2024, through August 8, 2024, and determined that the 072 Aspiration System (HIPPO) is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. §351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the device as described and marketed. The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C.\nSpecifically, FDA cleared, under K222786, the device that you identified in your submission to the agency as the 072 Aspiration System with the following indications, “072 Aspiration Catheter: As part of the 072 Aspiration System, the 072 Aspiration Catheter with a compatible suction pump is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral - M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who failed IV t-PA therapy are candidates for treatment. Aspiration Tubing: As part of the 072 Aspiration System, the Aspiration Tubing is intended to connect the 072 Aspiration Catheter to a compatible suction pump.” The 072 Aspiration System that was presented to us was cleared under K222786 with a design that included a catheter shaft with an inner diameter of 0.072 inch and an outer diameter of 0.0855 inch for the entire catheter working length. The submission that we numbered K222786 did not describe technological characteristics of the distal nitinol tip that would enable expansion of the distal tip to larger diameters or compression of the distal tip during clinical use. However, your firm’s promotion of the device and information collected during the inspection provides evidence that the device as it was designed and developed but not described in your submission includes a nitinol tip with technological characteristics that allow for expansion in diameter and compression in length, i.e., a device for which your firm lacks clearance or approval. Examples of the promotion and information include:\n(b)(4) data report of tip compression testing (“Hippo Tip Vacuum Ball Testing”) was shared via emails exchanged within Q’Apel Medical (b)(4). The data include tip diameter and length measurements of multiple catheter tips (“bad units” and “good units”) while vacuum was applied to a (b)(4) ball with a diameter larger than the HIPPO distal tip diameter. Multiple images show increased diameters of the distal region of the nitinol tip expanding around the surface of the (b)(4) ball with reported increases in diameters of (b)(4) for “good units” and increases in diameter of (b)(4) for “bad units.” The (b)(4) data reports tip diameters ranging from (b)(4) inch with aspiration applied to the (b)(4) ball, compared to the relaxed tip diameter of (b)(4) inch to (b)(4) inch. The (b)(4) data reports accompanying changes in tip length of (b)(4) (relaxed tip lengths of (b)(4) inch, compressed under ball aspiration to lengths of (b)(4) inch) for “good units” and (b)(4) (relaxed tip lengths of (b)(4) inch, compressed under ball aspiration to lengths of (b)(4) inch) for “bad units.” The distinction of “good units” and “bad units” is not described in the (b)(4) data. However, both “good units” and “bad units” describe evidence of increased HIPPO distal tip diameters and compressed tip lengths when aspiration was applied to the (b)(4) balls. The submission K222786 did not provide images or information to show expansion of the distal tantalum markers or compression of tip length of the nitinol tip as shown in the images included in the (b)(4) data of tip compression testing (“Hippo Tip Vacuum Ball Testing”).\nThe “(b)(4)” includes a video on page 35 of 45 titled “Mechanism of action,” that shows the nitinol tip of the HIPPO catheter aspirating a simulated clot. The video shows the catheter tip compress near the mid-point of the nitinol tip structure (with possible increased diameter), while the distal tantalum petal markers are obscured by the simulated clot. A second distinct slow-motion video also titled, “Mechanism of action,” is included on page 36 of 45 of the “(b)(4)” that shows the nitinol tip of the HIPPO catheter aspirating a simulated clot. This video shows the HIPPO catheter tip prior to contact with the simulated clot and upon contact with the simulated clot, the distal tantalum petal markers on the most distal struts of the nitinol tip are shown to flare at the edges combined with longitudinal compression of the nitinol tip while aspiration is applied to the clot until the clot is fully ingested through the catheter lumen. Page 37 of 45 of the “(b)(4)” includes a slow-motion video titled, “Mechanism of action: RED 72,” that shows aspiration of simulated clot with the cleared RED 72 Reperfusion Catheter (K211654) that was cited as a reference device during review of K222786 for the 072 Aspiration System (HIPPO). The video of the RED 72 Reperfusion Catheter does not show compression of the catheter tip or expansion of the distal catheter tip as observed in the videos of the HIPPO device on pages 35 and 36 of 45 of the “(b)(4).” Page 45 of 45 of the “(b)(4)” also includes a claim that the HIPPO provides “insightful navigation from a tip that flexes to any clot morphology.” The submission K222786 of the 072 Aspiration System (HIPPO) did not provide images that showed compression of the nitinol tip nor flaring of the distal petals of the nitinol tip as shown in videos presented in the “(b)(4).”\n• Drawing CS00788, “072 Catheter Nitinol Tip,” descriptions in the “Design History” notes that revision E updates included, “(b)(4).” The version of the drawing provided in K222786\u002FS001, Appendix 27, was revision D and did not include descriptions of (b)(4) specification changes or “(b)(4) compression testing with tip compression tool.” The “(b)(4), CS 00788 Catheter Nitinol Tip,” document number QI 01560 describes (b)(4). The images and test methods for compression of the nitinol tip were not described in drawing CS00788, revision D, provided in K222786. The submission K222786 otherwise did not provide images that showed compression of the nitinol tip as described in document QI 01560.\nDuring review of K222786, FDA asked for a description of the principle of operation and mechanism of action of the 072 Aspiration Catheter distal tip, including the tip dimensions related to the dimensions of the remainder of the catheter shaft, in the Refuse-to-Accept (RTA) notification dated September 30, 2022. The response provided in the document “002_Cover Letter_RTA_Final.pdf” of the K222786\u002FS001 submission dated October 24, 2022, stated that the 072 Aspiration Catheter tip had “the same Internal (0.072”) and External (0.0855”) dimensions (ID, OD) as the rest of the catheter’s usable length. The length of the tip is (b)(4)”. The flexible tip is a passive structure that does not have an active mechanism of action and is not self-expanding.” The information gathered in the inspection conducted July 29, 2024, through August 8, 2024, at your firm raises concerns that the information provided to FDA for review in K222786 did not accurately disclose the technological characteristics of the nitinol tip and the changes in diameter and length of the distal tip that could be exhibited during use conditions for aspiration of thrombus from patients experiencing acute ischemic stroke. These different technological characteristics of the nitinol tip to change in length and diameter constitute a change or modification in the device that could significantly affect the safety or effectiveness of the device (e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process) (21 CFR 807.81(a)(3)).\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the FDA. See 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nOur office requests that Q’Apel Medical cease any activities that result in the misbranding or adulteration of the 072 Aspiration System (HIPPO), such as the commercial distribution of the device for the uses discussed above.\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received response from Jim Talbot, Vice President Regulatory, Quality, and Clinical Affairs dated August 28, 2024, September 26, 2024, and November 27, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately document design input requirements as required by 21 CFR 820.30(c).\nFor example, your firm did not adequately define the physical, performance, and other design requirements for design inputs to include tip compression, aspiration\u002Fsuction pump, tip deflection, and treatment location for your firm’s 072 Aspiration System (Hippo), which are identified in your documents titled, Product Specification 072 Aspiration System (PS 00922, Rev. G) and Customer Requirement Specification Form (CRS 00848, Rev. D).\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm has not adequately defined specifications for tip elongation and compression (PS-11.5.2), aspiration flow rate (PS-11.5.3) and tip deflection (PS-11.5.9) that are identified in your document titled, Product Specification, PS 00922, Revision H.\nYour firm provided the document titled, Draft Research Report, Aspiration System, Aspiration Flowrate Acceptance Criteria, RR 02139, in your response dated August 28, 2024. This document appears to leverage previous testing of the Aspiration flowrate to define measurable acceptance criteria for future Aspiration Flowrate testing. The comparative device testing was conducted on a sample size of three (b)(4). The conclusion states an acceptance interval for the average flow rate is (b)(4). This value was not reflected in your Product Specification documentation or the Test Protocol, TP 00927, which is to be executed for future verification testing by a third-party service provider. It is not clear what this data will be used for.\nPlease evaluate the adequacy of your corrective actions related to design inputs and continue to provide us information related to your ongoing corrective actions.\n2. Failure to adequately establish and maintain procedures for design verification as required by 21 CFR 820.30(f).\nFor example, your firm did not adequately define acceptance criteria that can be verified for Aspiration Flowrate, Tip Deflection, and Tip Compression and Elongation in your protocol titled, Test Protocol, Device Performance Design Verification Validation, FG 00806, FG 00995 (TP 00927, Rev. C).\nAdditionally, the verification test performed for Aspiration Flowrate and documented in Test Report 072 Aspiration System, Design Verification Validation, FG00806, FG 00995, Aspiration Flowrate (TR 00927-15, Rev. A), was conducted using (b)(4) vacuum setting, whereas the Instructions for Use for the device describes (b)(4) vacuum settings the device can be used with. There is no documented rationale to justify why testing flowrate at (b)(4) setting is adequate.\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm still has not implemented your design control procedure, in that your design verification protocol continues to not establish acceptance criteria for specifications to include tip deflection, elongation and compression, and aspiration flow rate that can be verified. Additionally, your firm’s rationale for testing a (b)(4) vacuum pressure is inadequate. Verification testing should be performed for all (b)(4) ranges utilized by the device.\nYour firm stated that you are (b)(4). However, the Test Report has not been provided to FDA.\nPlease evaluate the adequacy of your corrective actions related to design verification and continue to provide us information related to your ongoing corrective actions.\n3. Failure to adequately establish and maintain procedures for design change as required by 21 CFR 820.30(i).\nFor example, your firm has not implemented your procedure for design changes titled, Design Control (SOP 00003, Rev. C, effective date 02\u002F01\u002F2021 & Rev. D, effective date 11\u002F14\u002F2022) (revisions in effect when design changes were processed), which states that design changes are subject to original verification or validation tests and if no test(s) or a subset is planned, a justification is required. Specifically, your firm has not evaluated the impact changes may have to original verification or validation tests or provided a justification if no test(s) or a subset is required. Design changes were made to update the specification for your 072 Cather, Nitinol Tip (b)(4) (under ECO 1142) and to update the (b)(4) specification (under ECO 1360) (b)(4) acceptability range (b)(4). No assessment was documented of the potential impact the changes could have on completed verification and\u002For validation tests.\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s reevaluation of ECO 1360 states that the firm’s risk management document, RM 00951, Design FMEA, 072 Aspiration System, was updated in ECO 1300 to capture the new risk identified with SA 00570 (b)(4). It further states that testing was performed via (b)(4). Your firm determined that verification and\u002For validation testing was not required. This assessment is inadequate. Testing should be documented and performed according to a defined protocol.\nPlease evaluate the adequacy of your corrective actions related to design changes and continue to provide us information related to your ongoing corrective actions.\n4. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a).\nFor example, your firm has not adequately implemented your complaint procedure, Complaint Handling and Customer Feedback (SOP 00148, Rev. M, effective date 02\u002F27\u002F2024), which requires returned product analysis to be completed within 30 days after receiving the product from the field. Specifically,\nCN 0251 was opened to document a complaint reporting resistance was felt while the Hippo 072 Aspiration Catheter was inside an access catheter. The associated complaint product was received by your firm on 06\u002F12\u002F2024 under RMA0494 and logged in RMA log. As of 08\u002F02\u002F2024 the complaint product has not been investigated.\nCN 0252 was opened to document a complaint reporting stretching on the distal portion of the 072 Aspiration Tubing. The associated complaint product was received by your firm on 06\u002F27\u002F2024 under RMA0493 and logged in RMA log. As of 08\u002F02\u002F2024 the complaint product has not been investigated.\nWe reviewed your firm’s response and conclude that it is not adequate. Removing the 30-day timeframe for completing the returned product analysis may impact your firm’s assessment of complaints that are determined to be malfunctions and thus your firm’s adherence to reporting timeframes required as part of the Medical Device Reporting (MDR) Regulation (see 21 CFR Part 803). Your firm should provide a risk-based justification for the removal of the requirement and evaluate complaints to determine if any unreported MDRs were found.\n5. Failure to adequately establish and maintain procedures for document control as required by 21 CFR 820.40.\nFor example, your firm did not adequately implement your document control procedures as outlined in (b)(4) (SOP 00002, Rev. R, effective date 05\u002F24\u002F2024 (current revision), Rev. P, effective date 02\u002F02\u002F2024, and Rev. N, effective date 07\u002F14\u002F2023. Section 6.1 of your procedure titled (b)(4) (SOP 00460, Rev, A, effective date 9\u002F14\u002F2020) (b)(4). Specifically, the following promotional material for the 072 Aspiration System (Hippo) was not developed and approved per the firm’s document control procedures:\nA video clip depicting the tip of the Hippo aspiration catheter flaring out\nA video clip referring the to the Hippo aspiration catheter tip as adaptive, depicting the tip of the Hippo aspiration catheter flaring out, and referencing R&D Aspiration Grip Force data\nA press release announcing the clearance of the Hippo 072 Aspiration System that describes the aspiration tip as adaptive\nWe reviewed your firm’s response and cannot determine the adequacy at this time. Your firm extended the target completion date to 11\u002F25\u002F2025, for compiling of a list of marketing\u002F promotional content for their Armadillo and Walrus devices and evaluating if product claims were found. (b)(4); therefore, we request that you continue to provide information related to the (b)(4).\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via e-mail to: Jessica Mu, Assistant Director at CDRHWarningLetterResponses@fda.hhs.gov. Refer to the Unique Identification Number, CMS # 699244, when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov or 619-941-3763.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nRDML Sean M. Boyd, MPH, USPHS\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Q’Apel Medical, Inc.","qapel-medical-inc-699244-02052025","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fqapel-medical-inc-699244-02052025","2026-10-26T08:09:46.009809+00:00","Warning Letter","Issued","2025-03-11","699244","Medical Devices","Jodie C. Fam","2026-08-19T16:59:01.909+00:00","VIA Electronic Mail","2025-02-05",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":18,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":47,"body_fetched_at":48,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},1152,[34,35,36,11,37,13,13,13],"\u003Ctime datetime=\"2024-11-26T14:20:00Z\">11\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-11T04:00:00Z\">10\u002F11\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadept-medical-ltd-692226-10112024\">Adept Medical Ltd. \u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Murray Fenton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder, CEO and Guiding Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Adept Medical Ltd. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2-6 Mc Donald Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Morningside\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Auckland\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New Zealand\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 11, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Fenton:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Auckland, New Zealand on May 13, 2024, through May 16, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Tympanostomy Tubes \"NeoZoline Ventilation Tubes\". Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. §351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Ms. Yi Huang, Quality and Regulatory Manager dated June 13, 2024, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures for acceptance activities, which include inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cp>1) Your firm's current incoming inspection and acceptance procedure for Biological Indicator \u003Cstrong>(b)(4)\u003C\u002Fstrong> (BI) is not adequately established. This inadequacy could compromise the sterilization process, potentially affecting the safety and effectiveness of the NeoZoline V ntilation Tubes. Your firm discards the Certificate of Conformance provided by&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> with each BI batch, which was requested by the FDA investigator during the inspection. It appears that your firm failed to retain critical documents such as the reconciliation sheet, production batch record, or \u003Cstrong>(b)(4)\u003C\u002Fstrong> Certification of Conformance, which are required under your own WI22 \"Production QC and Release Product Register,\" specifically section 2.3, to demonstrate that the product was successfully sterilized. The inspection revealed that your firm does not perform BI Population verification tests on the received BI batches to ensure that the population has not changed during shipping or storage. This is a critical step is necessary to provide a high degree of assurance that the BIs are viable to support verification that finished product is successfully sterilized through the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Sterilization process. Additionally, the inspection revealed that critical information such as the batch number and expiration date of the BI used in the sterile load is not documented on the post-sterilization B1 Test Reports, which are used as part of the finished device acceptance and release process.\u003C\u002Fp>\n\n\u003Cp>2) Your firm's incoming inspection and acceptance procedure for Sterile Potties (M1421, M1422) used for storing ultrasound cleaned NeoZoline Ventilation Tubes is not adequately established. The inspection revealed that your firm accepts incoming sterile pottle lots without a Certificate of Sterilization from the supplier. \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm stated that no additional testing or verification is performed to ensure the sterility of the incoming potties.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on June 1, 2024. Your firm concluded that a risk analysis of the specific observation indicates no risk to end users for products currently in distribution and manufacturing. That conclusion is based on the following factors:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Biological Indicator is an off the shelf product from supplier where \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;has claimed compliance with ISO 11138-1:2017 and ISO 11138-2:2017.\u003C\u002Fli>\n\t\u003Cli>The BI is packaged in a foil pouch designed to protect the product from humidity excursions.\u003C\u002Fli>\n\t\u003Cli>The potties are used to store non-sterile Ventilation Tubes hence the sterility of the pottle is not a requirement.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your firm has outlined a plan with the following actions to be completed by December 1, 2024, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on your firm's response there is an ambiguity in the definition of the term `pottle' and whether it is required to be sterile or not. \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>your firm's response states that there is no risk for the stenle products manufactured at your facility because the BIs that they use conform to ISO 11138-1:2017 and ISO 11138-2:2017, and that they are in their sterile packaging until they are needed. However, the inspection demonstrated that your firm does not do any testing to verify that the BIs purchased for the purpose of demonstrating that terminal sterilization is achieved, are actually viable when they are used. Additionally, the inspection revealed that they do not capture key data such as BI batch number and expiration date, and thus if a BI falsely indicated that a sterilization was successful, there is no mechanism by which your firm can trace the lots of sterile products back to a failed BI.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm did not include documentation or evidence of the corrections or corrective actions because they are in progress and have not been completed. Additionally, given the observations described above, your firm has not provided a commitment to conduct a retrospective assessment of all finished devices whose sterilization was verified using Biological Indicator \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>to determine whether sterility was compromised.\u003C\u002Fp>\n\n\u003Cp>2. Failure to ensure that where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a). For example:\u003C\u002Fp>\n\n\u003Cp>1) Your firm's ultrasonic cleaning process using the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Cleaner&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>is not adequately validated according to your firm's Manufacturing Process&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>During the inspection, FDA's investigator revealed that the ultrasonic cleaning process was not adequately validated because critical details—such as the description of the NeoZoline Ventilation Tube (including part number, size, and shape), the number of validation batches (runs), validation batch size, and sample size used—were not documented.\u003C\u002Fp>\n\n\u003Cp>2) During the inspection, your firm stated that it had not validated the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>process for the NeoZoline Ventilation Tube&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm&nbsp;stated that the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.&nbsp; Adept Medical also confirmed during the inspection that&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;had not validated the NeoZoline Ventilation Tube&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and that prior to Spring 2023,&nbsp;\u003Cstrong>(b)(4) \u003C\u002Fstrong>the\u003Cstrong>&nbsp;\u003C\u002Fstrong>NeoZoline Ventilation Tube \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>who also did not have a&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> NeoZoline Ventilation Tube.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates its Initial Action was completed on June 1, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors, based on the following factors:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>There is an existing validated sterilization process indicating a sterility assurance level of \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Annual bioburden results of pre-cleaned devices have bioburden levels below&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU.\u003C\u002Fli>\n\t\u003Cli>Current validation data, although not well documented in its sample selection and setting, still indicated the current setting provided adequate bioburden results, well within the capability of the sterilization process.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, your firm has not provided any evidence to substantiate your claims that the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>sterility assurance level or the bioburden limits below \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU were consistently achievable. The inspection raised concerns about your firm sterilization process, as discussed in the above section regarding compliance with 21 CFR 820.80(a). It is noteworthy that FDA requested validation documents for the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Cleaner during the May 2024 inspection and did not receive any documentation to indicate that this process was validated.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100. For example:\u003C\u002Fp>\n\n\u003Cp>Your firm's Corrective and Preventive Action (CAPA) procedure (M05-03) fails to ensure that:\u003C\u002Fp>\n\n\u003Cp>1) The quality data is adequately analyzed to identify potential and existing causes of nonconformances or other quality issues. Your firm stated to the FDA investigator that, although data is analyzed, they do not evaluate the results to determine whether any corrective or preventive actions are necessary, as required by 21 CFR 820.100(a)(3).\u003C\u002Fp>\n\n\u003Cp>2) Your firm failed to adequately verify the effectiveness of corrective actions for several CAPAs before closing them. Specifically, CAPAs CA-459, CA-438, and CA-437 were closed after implementing corrective actions, but your firm did not verify the effectiveness of these actions, as required by 21 CFR 820.100(a)(4).\u003C\u002Fp>\n\n\u003Cp>3) CA-429 was closed on February 16, 2023; at the time of the inspection, your firm stated that they had not started any of the corrective actions identified in the CAPA. As a result of the discussion during the inspection, your firm volunteered to mark the CAPA as 'open,' so that the corrective actions could be implemented.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that although procedure&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>the procedure did not instruct how to this data should be analyzed, and what subsequent actions should be taken once the data analysis is complete. However, your firm's procedure&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm has outlined the following plan to be completed by April 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, your firm's response does not identify conducting a retrospective analysis for all past CAPAs, to determine the impact of the lack of data analysis, and whether the appropriate corrective and\u002For preventive action was taken to address each CAPA's root cause. Additionally, your firm did not identify what actions it would take to address the lack of implementation of identified corrective actions and whether that issue is a systemic problem.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product; and failure to ensure that the evaluation includes a determination of the need for an investigation, as required by 21 CFR 820.90(a). For example:\u003C\u002Fp>\n\n\u003Cp>The FDA investigator reviewed six NC records related to your firm's NeoZoline Ventilation Tubes. All six NC records were closed (NC-2516, NC-2767, NC-2641, NC-2640, NC-2738, NC-2523), but showed the following deficiencies in documentation:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The NC records did not adequately document the evaluation of the identified nonconformities.\u003C\u002Fli>\n\t\u003Cli>The rationale for not conducting related investigations was inadequately documented in all six NC records.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm explained that incoming NeoZoline Ventilation Tubes \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>are not inspected upon arrival.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>Your firm further stated that they \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>This target achievement was cited as the reason for not taking further action.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors. That conclusion is based on postmarket surveillance data, which shows no product safety or performance complaints since the product's launch. However, a lack of documented safety signals does not ensure that nonconforming product was controlled and not introduced into commerce.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm has outlined a plan to be completed by April 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, your firm did not include documentation to demonstrate that it has evaluated or will evaluate all past non-conformances against your new procedure to determine whether additional corrective action was required to address the non-conformances identified in your NC Records.\u003C\u002Fp>\n\n\u003Cp>5. Failure to define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50(a)(2). For example:\u003C\u002Fp>\n\n\u003Cp>During the inspection, your firm was asked whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the NeoZoline ventilation tubes was validated&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm stated you have no knowledge or documentation regarding&nbsp;whether the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>for the NeoZoline Ventilation Tubes had been properly&nbsp;validated.&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Adept Medical learned the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Adept Medical received \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;units of NeoZoline Ventilation Tubes in various types from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;between June 2023 and November 2023. They released \u003Cstrong>(b)(4) \u003C\u002Fstrong>units\u003Cstrong>&nbsp;\u003C\u002Fstrong>(\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>boxes) of the NeoZoline Ventilation Tubes to the United States. Prior to June 2023, all NeoZoline Ventilation Tubes were \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;&nbsp;\u003C\u002Fstrong>Adept has failed to ensure that the conditions of the supplier agreement were adhered to by your supplier.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to the end users for products currently in supply and with distributors, based on the following considerations:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The post-market periodic safety update report (PSUR) on Ventilation Tubes supplied by \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>indicated no adverse events.\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Post market surveillance data indicated we have had no product safety or performance complaints since product launch.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, a lack of adverse events in post market safety signals does not provide assurance that the device meets its design specifications, in light of the fact that, Adept Medical was unaware that your supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;the NeoZoline Ventilation Tube \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>did not have any documentation that the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>device was validated.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, based on your firm's response, it is unclear how you intend to evaluate suppliers' compliance with 21 CFR Part 820, the Quality System Regulation.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the NeoZoline Ventilation Tubes are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PM_A) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, in that your firm did not notify FDA regarding a significant change or modification in the device that could significantly affect the safety or effectiveness of the device, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 C.F.R. 807.81 (a)(3)(i).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has modified the NeoZoline Ventilation Tubes cleared under K061058. The modification involves the use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;which was not cleared in the original submission and is a change that could significantly affect the safety or effectiveness of the device. This modification necessitates a comprehensive risk assessment to ensure the device remains safe and effective. A new biocompatibility evaluation is required to determine if \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>Any \u003Cstrong>(b)(4)\u003C\u002Fstrong> may affect how the device can be safely and effectively sterilized. Thus, your sterilization processes must be validated for the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure that it can be properly sterilized without&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> becoming unsafe. The change in \u003Cstrong>(b)(4)\u003C\u002Fstrong> may alter the device's performance or specifications, so a thorough re-evaluation is necessary to ensure it still meets all necessary standards and functions as intended. Due to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> modification and its potential impact on the device's safety and performance, a new 510(k) submission is required before marketing the modified device in the United States.\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #692226 when replying. If you have any questions about the contents of this letter, please contact: Shu-Chen Peng, Ph.D. at 301-796-6481.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Malvina B. Eydelman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT1: Office of Ophthalmic, Anesthesia,\u003Cbr>\nRespiratory, ENT and Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\n\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Registrar Corp.,\u003Cbr>\n144 Research Drive,\u003Cbr>\nHampton, Virginia,\u003Cbr>\nUSA 23666\u003Cbr>\nPhone: Tel: 1-757-224-0177, Ext.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\nEmail:\u003Cstrong>(b)(4)\u003C\u002Fstrong>@registrarcorp.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Murray Fenton\n\nRecipient Title\n\nFounder, CEO and Guiding Director\n\nAdept Medical Ltd.\n\n2-6 Mc Donald Street\n\nMorningside\n\nAuckland\n\nNew Zealand\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nOctober 11, 2024\n\nDear Mr. Fenton:\n\nDuring an inspection of your firm located in Auckland, New Zealand on May 13, 2024, through May 16, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Tympanostomy Tubes \"NeoZoline Ventilation Tubes\". Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. §351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Ms. Yi Huang, Quality and Regulatory Manager dated June 13, 2024, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for acceptance activities, which include inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\n\nFor example:\n\n1) Your firm's current incoming inspection and acceptance procedure for Biological Indicator (b)(4) (BI) is not adequately established. This inadequacy could compromise the sterilization process, potentially affecting the safety and effectiveness of the NeoZoline V ntilation Tubes. Your firm discards the Certificate of Conformance provided by (b)(4) with each BI batch, which was requested by the FDA investigator during the inspection. It appears that your firm failed to retain critical documents such as the reconciliation sheet, production batch record, or (b)(4) Certification of Conformance, which are required under your own WI22 \"Production QC and Release Product Register,\" specifically section 2.3, to demonstrate that the product was successfully sterilized. The inspection revealed that your firm does not perform BI Population verification tests on the received BI batches to ensure that the population has not changed during shipping or storage. This is a critical step is necessary to provide a high degree of assurance that the BIs are viable to support verification that finished product is successfully sterilized through the (b)(4) Sterilization process. Additionally, the inspection revealed that critical information such as the batch number and expiration date of the BI used in the sterile load is not documented on the post-sterilization B1 Test Reports, which are used as part of the finished device acceptance and release process.\n\n2) Your firm's incoming inspection and acceptance procedure for Sterile Potties (M1421, M1422) used for storing ultrasound cleaned NeoZoline Ventilation Tubes is not adequately established. The inspection revealed that your firm accepts incoming sterile pottle lots without a Certificate of Sterilization from the supplier. (b)(4). Your firm stated that no additional testing or verification is performed to ensure the sterility of the incoming potties. (b)(4)\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on June 1, 2024. Your firm concluded that a risk analysis of the specific observation indicates no risk to end users for products currently in distribution and manufacturing. That conclusion is based on the following factors:\n\nThe (b)(4) Biological Indicator is an off the shelf product from supplier where (b)(4) has claimed compliance with ISO 11138-1:2017 and ISO 11138-2:2017.\n\nThe BI is packaged in a foil pouch designed to protect the product from humidity excursions.\n\nThe potties are used to store non-sterile Ventilation Tubes hence the sterility of the pottle is not a requirement.\n\nAdditionally, your firm has outlined a plan with the following actions to be completed by December 1, 2024, which includes the following actions:\n\n(b)(4)\n\nBased on your firm's response there is an ambiguity in the definition of the term `pottle' and whether it is required to be sterile or not. (b)(4) your firm's response states that there is no risk for the stenle products manufactured at your facility because the BIs that they use conform to ISO 11138-1:2017 and ISO 11138-2:2017, and that they are in their sterile packaging until they are needed. However, the inspection demonstrated that your firm does not do any testing to verify that the BIs purchased for the purpose of demonstrating that terminal sterilization is achieved, are actually viable when they are used. Additionally, the inspection revealed that they do not capture key data such as BI batch number and expiration date, and thus if a BI falsely indicated that a sterilization was successful, there is no mechanism by which your firm can trace the lots of sterile products back to a failed BI.\n\nAdditionally, your firm did not include documentation or evidence of the corrections or corrective actions because they are in progress and have not been completed. Additionally, given the observations described above, your firm has not provided a commitment to conduct a retrospective assessment of all finished devices whose sterilization was verified using Biological Indicator (b)(4) to determine whether sterility was compromised.\n\n2. Failure to ensure that where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a). For example:\n\n1) Your firm's ultrasonic cleaning process using the (b)(4) Cleaner (b)(4) is not adequately validated according to your firm's Manufacturing Process (b)(4). During the inspection, FDA's investigator revealed that the ultrasonic cleaning process was not adequately validated because critical details—such as the description of the NeoZoline Ventilation Tube (including part number, size, and shape), the number of validation batches (runs), validation batch size, and sample size used—were not documented.\n\n2) During the inspection, your firm stated that it had not validated the (b)(4) process for the NeoZoline Ventilation Tube (b)(4). Your firm stated that the (b)(4). Adept Medical also confirmed during the inspection that (b)(4) had not validated the NeoZoline Ventilation Tube (b)(4) and that prior to Spring 2023, (b)(4) the NeoZoline Ventilation Tube (b)(4) who also did not have a (b)(4) NeoZoline Ventilation Tube.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates its Initial Action was completed on June 1, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors, based on the following factors:\n\nThere is an existing validated sterilization process indicating a sterility assurance level of (b)(4)\n\nAnnual bioburden results of pre-cleaned devices have bioburden levels below (b)(4) CFU.\n\nCurrent validation data, although not well documented in its sample selection and setting, still indicated the current setting provided adequate bioburden results, well within the capability of the sterilization process.\n\nAdditionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, your firm has not provided any evidence to substantiate your claims that the (b)(4) sterility assurance level or the bioburden limits below (b)(4) CFU were consistently achievable. The inspection raised concerns about your firm sterilization process, as discussed in the above section regarding compliance with 21 CFR 820.80(a). It is noteworthy that FDA requested validation documents for the (b)(4) Cleaner during the May 2024 inspection and did not receive any documentation to indicate that this process was validated.\n\n3. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100. For example:\n\nYour firm's Corrective and Preventive Action (CAPA) procedure (M05-03) fails to ensure that:\n\n1) The quality data is adequately analyzed to identify potential and existing causes of nonconformances or other quality issues. Your firm stated to the FDA investigator that, although data is analyzed, they do not evaluate the results to determine whether any corrective or preventive actions are necessary, as required by 21 CFR 820.100(a)(3).\n\n2) Your firm failed to adequately verify the effectiveness of corrective actions for several CAPAs before closing them. Specifically, CAPAs CA-459, CA-438, and CA-437 were closed after implementing corrective actions, but your firm did not verify the effectiveness of these actions, as required by 21 CFR 820.100(a)(4).\n\n3) CA-429 was closed on February 16, 2023; at the time of the inspection, your firm stated that they had not started any of the corrective actions identified in the CAPA. As a result of the discussion during the inspection, your firm volunteered to mark the CAPA as 'open,' so that the corrective actions could be implemented.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that although procedure (b)(4) the procedure did not instruct how to this data should be analyzed, and what subsequent actions should be taken once the data analysis is complete. However, your firm's procedure (b)(4)\n\nYour firm has outlined the following plan to be completed by April 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, your firm's response does not identify conducting a retrospective analysis for all past CAPAs, to determine the impact of the lack of data analysis, and whether the appropriate corrective and\u002For preventive action was taken to address each CAPA's root cause. Additionally, your firm did not identify what actions it would take to address the lack of implementation of identified corrective actions and whether that issue is a systemic problem.\n\n4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product; and failure to ensure that the evaluation includes a determination of the need for an investigation, as required by 21 CFR 820.90(a). For example:\n\nThe FDA investigator reviewed six NC records related to your firm's NeoZoline Ventilation Tubes. All six NC records were closed (NC-2516, NC-2767, NC-2641, NC-2640, NC-2738, NC-2523), but showed the following deficiencies in documentation:\n\nThe NC records did not adequately document the evaluation of the identified nonconformities.\n\nThe rationale for not conducting related investigations was inadequately documented in all six NC records.\n\nYour firm explained that incoming NeoZoline Ventilation Tubes (b)(4) are not inspected upon arrival. (b)(4). Your firm further stated that they (b)(4). This target achievement was cited as the reason for not taking further action.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors. That conclusion is based on postmarket surveillance data, which shows no product safety or performance complaints since the product's launch. However, a lack of documented safety signals does not ensure that nonconforming product was controlled and not introduced into commerce.\n\nAdditionally, your firm has outlined a plan to be completed by April 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, your firm did not include documentation to demonstrate that it has evaluated or will evaluate all past non-conformances against your new procedure to determine whether additional corrective action was required to address the non-conformances identified in your NC Records.\n\n5. Failure to define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50(a)(2). For example:\n\nDuring the inspection, your firm was asked whether the (b)(4) for the NeoZoline ventilation tubes was validated (b)(4). Your firm stated you have no knowledge or documentation regarding whether the (b)(4) for the NeoZoline Ventilation Tubes had been properly validated. (b)(4) Adept Medical learned the (b)(4) Adept Medical received (b)(4) units of NeoZoline Ventilation Tubes in various types from (b)(4) between June 2023 and November 2023. They released (b)(4) units ((b)(4) boxes) of the NeoZoline Ventilation Tubes to the United States. Prior to June 2023, all NeoZoline Ventilation Tubes were (b)(4). Adept has failed to ensure that the conditions of the supplier agreement were adhered to by your supplier.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to the end users for products currently in supply and with distributors, based on the following considerations:\n\nThe post-market periodic safety update report (PSUR) on Ventilation Tubes supplied by (b)(4) indicated no adverse events.\n\n(b)(4)\n\nPost market surveillance data indicated we have had no product safety or performance complaints since product launch.\n\nHowever, a lack of adverse events in post market safety signals does not provide assurance that the device meets its design specifications, in light of the fact that, Adept Medical was unaware that your supplier (b)(4) the NeoZoline Ventilation Tube (b)(4) did not have any documentation that the (b)(4) device was validated.\n\nAdditionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, based on your firm's response, it is unclear how you intend to evaluate suppliers' compliance with 21 CFR Part 820, the Quality System Regulation.\n\nOur inspection also revealed that the NeoZoline Ventilation Tubes are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PM_A) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, in that your firm did not notify FDA regarding a significant change or modification in the device that could significantly affect the safety or effectiveness of the device, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 C.F.R. 807.81 (a)(3)(i).\n\nSpecifically, your firm has modified the NeoZoline Ventilation Tubes cleared under K061058. The modification involves the use of a (b)(4) which was not cleared in the original submission and is a change that could significantly affect the safety or effectiveness of the device. This modification necessitates a comprehensive risk assessment to ensure the device remains safe and effective. A new biocompatibility evaluation is required to determine if (b)(4). Any (b)(4) may affect how the device can be safely and effectively sterilized. Thus, your sterilization processes must be validated for the (b)(4) to ensure that it can be properly sterilized without (b)(4) becoming unsafe. The change in (b)(4) may alter the device's performance or specifications, so a thorough re-evaluation is necessary to ensure it still meets all necessary standards and functions as intended. Due to the (b)(4) modification and its potential impact on the device's safety and performance, a new 510(k) submission is required before marketing the modified device in the United States.\n\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm's response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #692226 when replying. If you have any questions about the contents of this letter, please contact: Shu-Chen Peng, Ph.D. at 301-796-6481.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nMalvina B. Eydelman, M.D.\n\nDirector\n\nOHT1: Office of Ophthalmic, Anesthesia,\n\nRespiratory, ENT and Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\n(b)(4), Registrar Corp.,\n\n144 Research Drive,\n\nHampton, Virginia,\n\nUSA 23666\n\nPhone: Tel: 1-757-224-0177, Ext. (b)(4)\n\nEmail:(b)(4)@registrarcorp.com","Adept Medical Ltd.","adept-medical-ltd-692226-10112024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadept-medical-ltd-692226-10112024","2026-10-26T08:07:50.120298+00:00","2024-11-26","692226","Mr. Murray Fenton","2026-08-19T17:57:49.713+00:00","Via Email","2024-10-11",{"id":52,"raw":53,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":19,"body_fetched_at":69,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":70,"medical_device_id":19,"response_letter_date":19},472,[54,55,56,57,58,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-13T05:00:00Z\">11\u002F13\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025\">Medical Mega\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Medical Mega\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>208 Fairmont Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jersey City\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07306\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Sales@medicalmega.com\"> Sales@medicalmega.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 13, 2025\u003C\u002Fp>\u003Cp>RE: 717840\u003C\u002Fp>\u003Cp>Medical Mega:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\u003C\u002Fp>\u003Cp>With respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&amp;C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\u003C\u002Fp>\u003Cp>Therefore, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&amp;C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>In addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&amp;C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nMedical Mega\n\n208 Fairmont Ave\n\nJersey City, NJ 07306\n\nUnited States\n\nSales@medicalmega.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nNovember 13, 2025\nRE: 717840\nMedical Mega:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\n“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\nBased on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\nWith respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\nTherefore, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nIn addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_________________\n1 On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).","Medical Mega","medical-mega-717840-11132025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025","2026-10-26T08:09:22.956521+00:00","2025-11-18","717840","Drugs","2026-08-19T14:27:25.954+00:00","2025-11-13",{"id":72,"raw":73,"subject":77,"body_html":78,"body_text":79,"firm_name":80,"letter_id":81,"created_at":63,"fei_number":19,"letter_url":82,"updated_at":83,"action_type":22,"case_status":23,"posted_date":84,"marcs_cms_no":85,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":86,"body_fetched_at":87,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":88,"medical_device_id":19,"response_letter_date":19},266,[74,75,76,11,77,13,13,13],"\u003Ctime datetime=\"2026-03-17T04:00:00Z\">03\u002F17\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-03T04:00:00Z\">09\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Favertix-medical-inc-711080-09032025\">Avertix Medical, Inc.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Timothy P. Moran\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Avertix Medical, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>40 Christopher Way, Ste 201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Eatontown\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07724\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:tmoran@avertix.com\"> tmoran@avertix.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 711080\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 3, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Moran:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Eatontown, NJ from February 19, 2025, through March 11, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures The Guardian System, an implantable coronary syndrome event detector. The Guardian System consists of three main system components: an implantable device used to monitor a patient’s electrogram (IMD); a hand-held telemetry device that provides alarms and alerts and interfaces between the IMD and programmer (EXD); and a programmer utilized by healthcare professionals to program the IMD and alarm\u002Falert settings and retrieve and review IMD data (Programmer). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received responses from David Keenan, Chief Technology Officer, dated March 31, 2025, and June 20, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to maintain complaint files; and failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a). Specifically, the firm’s procedure, Complaint Procedure, #1716-002, Rev Q (dated February 25, 2022) to Rev R (dated April 11, 2022) has not been adequately established in that:\u003C\u002Fp>\u003Cp>a. Your firm failed to adequately maintain complaint files, as required by 21 CFR 820.198(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, section 5.1.2 of your complaint procedure requires all employees to report any product complaint or feedback from the field. Section 5.1.3 of the complaint procedure covers the review of “ISSUES” to disposition them as a “COMPLAINT” or “REJCT\u002FNo ACTION REQUIRED”. The FDA investigator identified 11 issues which meet the definition of a complaint and were not dispositioned as a complaint as required by your procedure. For example:\u003C\u002Fp>\u003Cp>i. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reported on November 6, 2023, listing the patient effect description as “Guardian Device was removed from the patient due to a recurrent pocket infection post implant.”\u003C\u002Fp>\u003Cp>ii. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reported on March 4, 2022, listed the programmer battery connector broke when trying to remove the battery.\u003C\u002Fp>\u003Cp>iii. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reported on September 6, 2023, listed the USB Drive for Programmer was not connected and required formatting each time to use.\u003C\u002Fp>\u003Cp>Additionally, six of eleven “nonconforming material reports” (NCMRs) reviewed during the inspection that met the definition of complaints were not considered complaints and as such were handled according to your nonconforming material process. For example:\u003C\u002Fp>\u003Cp>iv. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, created April 30, 2024, states that a Programmer (PROG-003) was returned from the field due to issues with the battery charging indicator light.\u003C\u002Fp>\u003Cp>v. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, created September 6, 2023, states a USB flash drive was not functioning properly in the field and was returned.\u003C\u002Fp>\u003Cp>vi. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, created November 22, 2022, states that a field clinical engineer reported that a Programmer Battery was damaged while being inserted into the Programmer.\u003C\u002Fp>\u003Cp>The above “issues” and “nonconforming product reports” were not evaluated for MDR reportability and were not reviewed to determine if an investigation is necessary, since they were not considered complaints.\u003C\u002Fp>\u003Cp>b. Your firm failed to adequately establish and maintain procedures to ensure that all complaints are processed in a uniform and timely manner, as required by 21 CFR 820.198(a)(1).\u003C\u002Fp>\u003Cp>Specifically, your firm’s \u003Cem>Complaint Procedure\u003C\u002Fem>, #1716-002, does not include a requirement for timely and uniform complaint handling. For example, the following complaints were entered as issues and were not escalated to complaints in a timely manner:\u003C\u002Fp>\u003Cp>i. Complaint-00077: On July 17, 2024, your firm became aware of a reported issue where the physician was unable to retrieve data from the IMD implant. The complaint record was not opened until September 5, 2024 (50 days after becoming aware).\u003C\u002Fp>\u003Cp>ii. Complaint-00066: On February 13, 2024, your firm became aware of an IMD explant due to an infection. The complaint record was not opened until March 28, 2024 (44 days after becoming aware).\u003C\u002Fp>\u003Cp>iii. Complaint-00059: On November 30, 2023, your firm became aware of a reported “flat line IMD” event. The complaint record was not opened until January 5, 2024 (36 days after becoming aware).\u003C\u002Fp>\u003Cp>iv. Complaint-00039: On October 28, 2022, your firm became aware of an IMD explant due to an infection. The complaint record was not opened until December 1, 2022 (34 days after becoming aware).\u003C\u002Fp>\u003Cp>c. Your firm failed to review, evaluate, and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820 820.198(c).\u003C\u002Fp>\u003Cp>Specifically, Section 5.1.4 of your \u003Cem>Complaint Procedure\u003C\u002Fem> requires investigation of complaints. Your firm failed to adequately review, evaluate, and investigate the following complaints that reported patient infection and subsequent explant of the implantable cardiac monitoring device (IMD), the implantable portion of The Guardian System:\u003C\u002Fp>\u003Cp>i. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reported on February 13, 2024, that subsequently became Complaint-00066, documents the justification for not performing an investigation as: “\u003Cem>Physician determined patient had a pocket infection and made the decision to explant and device. No investigation needed\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>ii. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reported on October 28, 2022, that subsequently became Complaint-00039, documents the “Initiate Investigation Process” option was selected but no investigation was performed and the “\u003Cem>Review for Closure\u003C\u002Fem>” section of the complaint records lists “\u003Cem>no investigation needed\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. In the response, your firm states that CAPA 00015 was opened to capture all corrective and preventive work performed in relation to this observation. As part of CAPA 00015, your firm promised to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm also promised to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, the response does not address performing a retrospective review of all issues and nonconforming product reports to determine if other complaints exist and if investigations need to be performed. Several of the items promised by your firm continue to be in-progress (including but not limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR 820.90(a).\u003C\u002Fp>\u003Cp>Specifically, your \u003Cem>Nonconformance Material Procedure\u003C\u002Fem>, #1707-002, does not include a provision for the determination of the need for an investigation. For example, the following two nonconformances did not include a documented investigation or evaluation:\u003C\u002Fp>\u003Cp>a. \u003Cstrong>(b)(4)\u003C\u002Fstrong> was created on June 27, 2024, for IMD batteries that were sent to your contract manufacturer for use in production were returned due to nonconformances (bent prongs). The disposition of the batteries was recorded as being scrapped. However, there was no investigation conducted into the cause of the bent probes and the nonconformance record does not include a rationale for not investigating.\u003C\u002Fp>\u003Cp>b. \u003Cstrong>(b)(4)\u003C\u002Fstrong> was created on June 7, 2023, for the EXD-001 Battery Packaging Label (p\u002Fn \u003Cstrong>(b)(4)\u003C\u002Fstrong>) on the EXD-001 Battery, 10 Packs (p\u002Fn \u003Cstrong>(b)(4)\u003C\u002Fstrong>) listing an incorrect expiration date and battery lot code in finished goods inventory. Your firm reworked the nonconforming product. However, there was no investigation conducted into the cause of the incorrect labeling and the nonconformance record does not include a rationale for not investigating.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Your response promises to \u003Cstrong>(b)(4)\u003C\u002Fstrong> as well as plans to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. All activities are captured in CAPA 00017 and all work is promised by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your response fails to address if a retrospective review of NCMRs will be conducted. Several of these promised actions (including CAPA 00017) remain in-progress with a tentative CAPA Effectiveness Verification planned due date of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish and maintain procedures for validating the device design to include adequate risk analysis, as required by 21 CFR 820.30(g). Specifically, section 6.14 of your \u003Cem>Risk Management Procedure\u003C\u002Fem>, #1701-011, covers the information collection, information review, and actions related to the use of the Corrective and Preventive Action System and the Complaint System to monitor the device in the clinical and post-production phase to determine if reassessment of risks and\u002For assessment of new risks is necessary. Your firm failed to reassess the risk when estimated risks from a hazard differed from the actual risk observed in post-market CAPA and complaint data. For example:\u003C\u002Fp>\u003Cp>a. Your firm has received three complaints of infection with the IMD portion of the Guardian System out of a total of \u003Cstrong>(b)(4)\u003C\u002Fstrong> IMDs implanted as of February 25, 2025. The observed rate of infection is \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. In your device risk file, \u003Cem>Guardian System Risk Assessment\u003C\u002Fem> – P18, #0201-0200-001#P18, Rev B, dated November 13, 2023, the rate of infection was estimated to be \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. The risk was not reassessed.\u003C\u002Fp>\u003Cp>b. Your firm has received 24 complaints of battery failure due to electrical short before the device reached its expected service life of 6 years, causing patients to opt for early explant and\u002For replacement. The observed rate of battery failure is \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. In your device risk file, \u003Cem>IMD AMSG3-E Hardware FMECA Report – P16\u003C\u002Fem>, #0212-0201-001#P16, Rev A; dated February 24, 2015, the rate of battery failure was estimated to be \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Further, your firm initiated CAPA-00012 in response to the battery failures. The “Process Impacts” section of this CAPA indicates that no updates to risk management were needed. The risk was not reassessed.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. In the response, your firm indicates that CAPA 00016 was opened to address any corrective and preventive work taken as result of the observation including to assess the risk associated with infection using current performance data against historical data and to address the need to perform risk reviews on a regularly scheduled basis to keep the risk data current by July 1, 2025. However, your firm did not indicate if you intend to review, and update as necessary, the risk file utilizing post-market data for items other than risk of infection. Several of the items promised by your firm continue to be in-progress, including but not limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong> which has a \u003Cstrong>(b)(4)\u003C\u002Fstrong> planned due date of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm failed to follow your procedure, Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, when taking corrective and preventive actions. Two examples of lack of CAPA procedure implementation are as follows:\u003C\u002Fp>\u003Cp>a. Your firm failed to follow your CAPA process for a corrective action taken as a result of a consumer complaint which led to a revision made to manufacturing procedure Process Specification, PROG-004 Final Shipping Manufacturing, #0217-1200-020#P18, Rev F, dated November 19, 2024. These actions were taken outside of the CAPA system and lack a documented CAPA investigation as well as verification of implementation and effectiveness.\u003C\u002Fp>\u003Cp>b. Your firm failed to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). Specifically, section 5.9 of the Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, describes your firm’s process for establishing verification of effectiveness plans with predetermined criteria that verify if corrective and\u002For preventive actions were effective. Additionally, section 5.10 of the Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, describes the process for conducting the verification of effectiveness (VOE) phase to demonstrate effectiveness.\u003C\u002Fp>\u003Cp>Review of five CAPAs closed between January 2022 and the time of the current inspection disclosed that four CAPAs (CAPA-00007, CAPA-00008, CAPA-00010, and CAPA-00014) lacked evidence that your firm verified or validated that the action taken was effective.\u003C\u002Fp>\u003Cp>For example, CAPA-00007, was opened as a result of the previous inspection on March 15, 2022, related to a complaint involving EXD batteries having expired shelf life. Your firm implemented several corrective actions to correct the issue which were documented utilizing the complaint record (complaint number 00013) instead of through the CAPA system. CAPA-00007 was closed on March 31, 2022, without verifying the effectiveness of the correction and preventive actions taken.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. In this response, your firm opened CAPA 00016 to document actions taken for this observation. Your firm promises to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For the 5 CAPAs lacking VOE plans and reports, your firm asks our Agency if \u003Cstrong>(b)(4)\u003C\u002Fstrong> (2021 or earlier). The decision to \u003Cstrong>(b)(4)\u003C\u002Fstrong> remains your firm’s decision as long as it is based on a rationale you determine to be appropriate given the 21 CFR 820.100(a)(4) and your own procedural requirement to demonstrate effectiveness of a CAPA action. You are also going to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response does not address if other CAPAs will be reviewed to determine if \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Several of the items promised by your firm continue to be in-progress (including but not limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>5. Failure to validate with a high degree of assurance and approve according to established procedures, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). Specifically, your firm’s Process Validation Procedure, #1705-002, Rev E, dated October 23, 2020, and Process Qualification Procedure, #1705-001, Rev F, dated October 23, 2020, were not adequately established in that both procedures fail to address sterilization validation. Your firm’s implantable cardiac monitoring device (IMD) undergoes \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization. Further, the two procedures fail to document the process of requalification and revalidation (if necessary) of the sterilization cycle.\u003C\u002Fp>\u003Cp>For example, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process for your firm’s IMD was last performed in June 2022 by a 3rd party in accordance with FDA-recognized standard ANSI\u002FAAMI\u002FISO 11135:2014. Your firm has not reviewed the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process since the 2022 requalification.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. In the responses, you indicate that CAPA 00019 was opened as a result of the observation and that your firm promises to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your responses do not address if your firm’s plans to revise your process validation procedures to include sterilization. Additionally, supporting evidence (including CAPA 00019) of these promised actions remain in progress with a CAPA Effectiveness Verification planned due date for CAPA 00019 of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>6. Failure to adequately establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants, as required by 21 CFR 820.50(a). Specifically, your \u003Cem>Supplier Management Procedure\u003C\u002Fem> (#1703-003), has not been fully implemented. For example:\u003C\u002Fp>\u003Cp>a. Your firm’s \u003Cem>Supplier Management Procedure\u003C\u002Fem> (#1703-003) describes a process for supplier evaluation and acceptance using a supplier evaluation form. The Supplier Evaluation Form for the IMD battery supplier, (dated February 13, 2020), indicated your firm’s contract manufacturer would perform receiving inspections of these batteries and provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> to Avertix. Your QA\u002FQC manager stated these \u003Cstrong>(b)(4)\u003C\u002Fstrong> were not completed.\u003C\u002Fp>\u003Cp>b. Your firm failed to adequately establish and maintain records of acceptable suppliers, contractors, and consultants, as required by 21 CFR 820.50(a)(3). Specifically, section 7.1.12 of Supplier Management Procedure, Rev K, states that “Quality Assurance is responsible for revising the Approved Supplier List with changes made based on acceptance\u002Frejection of potential suppliers\u002Fre-evaluated suppliers\u002Fdeactivated suppliers…” A software supplier used by your firm since 2023 to meet the requirements of the Medical Device Tracking regulation was not listed on your Approved Supplier List (Rev L, dated June 15, 2023).\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. In the responses, your firm promises and provided revisions to your Supplier Management Procedure (Document 1703-003) removing the requirement for \u003Cstrong>(b)(4)\u003C\u002Fstrong> for your contract manufacturer and to evidence of a new supplier evaluation for the software supplier utilized for medical device tracking by July 1, 2025. The responses do not indicate if other supplier evaluations will be evaluated and updated, as needed. Further, CAPA 00023 remains in progress with a CAPA Effectiveness Verification planned due date of December 1, 2025.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Guardian System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 803 - Medical Device Reporting was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fp>\u003Cp>For example, the information included for Complaint-00066, Issue-00091, and Complaint-00039 reasonably suggests that each patient sustained an injury or illness (i.e., infection) following implantation of your firm’s Guardian System. These infections constituted serious injuries within the meaning of 21 CFR 803.3(w) because they necessitated surgical intervention (i.e., explantation) to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of information that reasonably suggests that the Guardian System may have caused or contributed to a serious injury on February 13, 2024, for Complaint-00066, on November 6, 2023, for Issue-00091, and on October 28, 2022, for Complaint-00039. As such, Complaint-00066, Issue-00091, and Complaint-00039 represent MDR reportable events, as defined in 21 CFR 803.3(o)(2)(i). However, the FDA did not receive an MDR for each referenced event until April 10, 2025, which exceeded the required 30 calendar day reporting timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. We acknowledge that the FDA received the manufacturer reports, submitted using the electronic equivalent of Form 3500A, for the referenced serious injury events after the 30 calendar day reporting timeframe had elapsed. However, although the response referenced the updated MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, as part of its correction action for the late reporting issue, a copy of the updated MDR procedure was not included.\u003C\u002Fp>\u003Cp>2. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\u003Cp>For example, the information included for Complaints No. 00057, 00065, 00070, 00071, 00072, 00074, 00077, 00079, 00080, 00082, 00083, and 00086, reasonably suggests that your firm’s Guardian System malfunctioned while in use. Specifically, the device prematurely reached its end of service due to early battery depletion, meaning that it failed to meet its performance specifications or otherwise perform as intended under 21 CFR 803.3(k). Your firm initiated recall Z-1140-2025 for the referenced malfunction. A malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the Act as a result of the malfunction of the device or other similar devices. See Medical Devices; Medical Device User Facility and Manufacturer Reporting, Certification and Registration, 60 Fed. Reg. 63585 (Dec. 11, 1995) (referring to section 519(f), which has since been redesignated as section 519(g)). As such, the referenced complaints represent MDR reportable events, as defined under 21 CFR 803.3(o)(2)(ii).\u003C\u002Fp>\u003Cp>Your firm became aware of information on the following dates that reasonably suggests that the Guardian System had malfunctioned and this device or a similar device your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur: October 10, 2023, for Complaint No. 00057; February 26, 2024, for 00065; May 28, 2024, for 00070; May 14, 2024, for 00071; May 5, 2024, for 00072; May 14, 2024, for 00074; July 17, 2024, for 00077; August 29, 2024, for 00079; August 21, 2024, for 00080; November 19, 2024, for 0008; November 19, 2024, for 00083; and December 3, 2024, for 00086. Your firm submitted a report for each event using the MedWatch Online Voluntary Reporting Form. Specifically, MW5149541 (Complaint No. 00057), MW5153561 (Complaint No. 00065), MW5159171 (Complaint No. 00070), MW5159172 (Complaint No.00071), MW5159173 (Complaint No. 00072), MW5159805 (Complaint No. 00074), MW5160629 (Complaint No. 00077), MW5160632 (Complaint No. 00079), MW5160633 (Complaint No. 00080), MW5164478 (Complaint No. 00082), MW5164476 (Complaint No. 00083), and MW5164481 (Complaint No. 00086). The submission of reports using the voluntary MedWatch Online Voluntary Reporting Form does not fulfill reporting obligations arising under 21 CFR Part 803. An electronic submission of a mandatory report from a manufacturer must contain the information from the applicable blocks of Form FDA 3500A. All medical device reports must be submitted within the required timeframes. However, the FDA did not receive the corresponding MDRs until April 14, 2025, which exceeded the required 30 calendar day reporting timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. We acknowledge that the FDA received the manufacturer reports, submitted using the electronic equivalent of Form 3500A, for the referenced malfunction events based on your firm’s retrospective review on April 14, 2025, after the 30 calendar day reporting timeframe had elapsed.\u003C\u002Fp>\u003Cp>However, although the response referenced the updated MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, as part of its correction action for the late reporting issue, a copy of the updated MDR procedure was not included.\u003C\u002Fp>\u003Cp>In addition, the inspection revealed that your firm failed to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, your firm presented the document titled “Medical Device Vigilance Procedures,” Document No. 1716-005, Rev. F, dated June 25, 2024, as its MDR procedure. Upon review, we conclude that the MDR procedure does not develop, maintain, and implement written MDR procedures for internal systems that provide for timely transmission of complete medical device reports to FDA, as required by 21 CFR 803.17(a)(3). Specifically, the procedure 1716-005, Rev. F does not include instructions for how your firm will comply with the 21 CFR 803.12(a) requirement to submit reports to FDA in an electronic format that FDA can process, review, and archive. As a manufacturer, you must submit reports of individual adverse events to FDA in an electronic format in accordance with 21 CFR 803.12(a) and 803.20, unless granted an exemption under 21 CFR 803.19.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. While your response included a copy of the updated Complaint Procedure, Document No.1716-002, and staff training records, it referenced an update to the MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, without including a copy. Without the referenced document, we cannot fully assess the adequacy of the response.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Guardian System Model AMSG3‐E IMD implant devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals was promulgated under section 519 of the Act, among other provisions. Violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit to the FDA within 10 working days of initiating a correction or removal a report required by 21 CFR 806.10.\u003C\u002Fp>\u003Cp>Specifically, on September 18, 2023, Avertix Medical, Inc., delivered a letter to physicians who have patients implanted with a Model AMSG3‐E IMD manufactured during the period when a contamination issue was occurring on the battery production line. This issue led to premature battery depletion in the Guardian System implants, which can result in failure to monitor and earlier‐than‐expected implant replacement surgery. The letter recommends reducing the interval of regular follow-up visits and reinforcing the patient training. FDA determined that shorter device implant life leading to sooner than expected replacement surgery may present a risk to health. This action constitutes a medical device correction or removal initiated to reduce a risk to health posed by the device or remedy a violation of the Act caused by the device which may present a risk to health under 21 CFR 806.10(a). Accordingly, you were required to submit a Report of Correction or Removal to FDA within 10 working days of initiation, under 21 CFR 806.10(b). You submitted a Medical Device Report of Correction or Removal to FDA for this action on December 11, 2024.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. The responses do not contain evidence that your firm’s procedures will result in compliance with the medical device correction and removal reporting requirements in 21 CFR 806. CAPA 00020 states that management failed to recognize that it needed to submit a Report of Correction or Removal within 10 working days of initiation. Your corrective action was retraining personnel in two procedures, Complaint Procedure (1716-002) and Vigilance Procedure (1716-005). You stated that your Quality Management System (QMS) procedure specifies that recalls or corrections must be reported within 10 days. However, your responses did not include a new revision of 1716-005 nor procedure 1716-004, PRODUCT RECALLS, CORRECTIONS AND REMOVALS. Procedure 1716-004 Rev F, collected in the inspection, notes that the Recall Coordinator is responsible for communicating with regulatory agencies within defined reporting times as per the Vigilance procedure. The procedure titled MEDICAL DEVICE VIGILANCE PROCEDURES, 1716-005 Rev F, collected during the inspection, does not describe Reports of Corrections or Removals, required by 21 CFR 806. Therefore, training personnel on 1716-005 will not help personnel know the timeframe for reporting a Medical Device Correction or Removal to FDA.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 711080” when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Compliance Officer at sean.moynihan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nTimothy P. Moran\n\nRecipient Title\n\nPresident and CEO\n\nAvertix Medical, Inc.\n\n40 Christopher Way, Ste 201\n\nEatontown, NJ 07724\n\nUnited States\n\ntmoran@avertix.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 711080\nSeptember 3, 2025\nDear Mr. Moran:\nDuring an inspection of your firm located in Eatontown, NJ from February 19, 2025, through March 11, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures The Guardian System, an implantable coronary syndrome event detector. The Guardian System consists of three main system components: an implantable device used to monitor a patient’s electrogram (IMD); a hand-held telemetry device that provides alarms and alerts and interfaces between the IMD and programmer (EXD); and a programmer utilized by healthcare professionals to program the IMD and alarm\u002Falert settings and retrieve and review IMD data (Programmer). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from David Keenan, Chief Technology Officer, dated March 31, 2025, and June 20, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to maintain complaint files; and failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a). Specifically, the firm’s procedure, Complaint Procedure, #1716-002, Rev Q (dated February 25, 2022) to Rev R (dated April 11, 2022) has not been adequately established in that:\na. Your firm failed to adequately maintain complaint files, as required by 21 CFR 820.198(a).\nSpecifically, section 5.1.2 of your complaint procedure requires all employees to report any product complaint or feedback from the field. Section 5.1.3 of the complaint procedure covers the review of “ISSUES” to disposition them as a “COMPLAINT” or “REJCT\u002FNo ACTION REQUIRED”. The FDA investigator identified 11 issues which meet the definition of a complaint and were not dispositioned as a complaint as required by your procedure. For example:\ni. (b)(4), reported on November 6, 2023, listing the patient effect description as “Guardian Device was removed from the patient due to a recurrent pocket infection post implant.”\nii. (b)(4), reported on March 4, 2022, listed the programmer battery connector broke when trying to remove the battery.\niii. (b)(4), reported on September 6, 2023, listed the USB Drive for Programmer was not connected and required formatting each time to use.\nAdditionally, six of eleven “nonconforming material reports” (NCMRs) reviewed during the inspection that met the definition of complaints were not considered complaints and as such were handled according to your nonconforming material process. For example:\niv. (b)(4), created April 30, 2024, states that a Programmer (PROG-003) was returned from the field due to issues with the battery charging indicator light.\nv. (b)(4), created September 6, 2023, states a USB flash drive was not functioning properly in the field and was returned.\nvi. (b)(4), created November 22, 2022, states that a field clinical engineer reported that a Programmer Battery was damaged while being inserted into the Programmer.\nThe above “issues” and “nonconforming product reports” were not evaluated for MDR reportability and were not reviewed to determine if an investigation is necessary, since they were not considered complaints.\nb. Your firm failed to adequately establish and maintain procedures to ensure that all complaints are processed in a uniform and timely manner, as required by 21 CFR 820.198(a)(1).\nSpecifically, your firm’s Complaint Procedure, #1716-002, does not include a requirement for timely and uniform complaint handling. For example, the following complaints were entered as issues and were not escalated to complaints in a timely manner:\ni. Complaint-00077: On July 17, 2024, your firm became aware of a reported issue where the physician was unable to retrieve data from the IMD implant. The complaint record was not opened until September 5, 2024 (50 days after becoming aware).\nii. Complaint-00066: On February 13, 2024, your firm became aware of an IMD explant due to an infection. The complaint record was not opened until March 28, 2024 (44 days after becoming aware).\niii. Complaint-00059: On November 30, 2023, your firm became aware of a reported “flat line IMD” event. The complaint record was not opened until January 5, 2024 (36 days after becoming aware).\niv. Complaint-00039: On October 28, 2022, your firm became aware of an IMD explant due to an infection. The complaint record was not opened until December 1, 2022 (34 days after becoming aware).\nc. Your firm failed to review, evaluate, and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820 820.198(c).\nSpecifically, Section 5.1.4 of your Complaint Procedure requires investigation of complaints. Your firm failed to adequately review, evaluate, and investigate the following complaints that reported patient infection and subsequent explant of the implantable cardiac monitoring device (IMD), the implantable portion of The Guardian System:\ni. (b)(4), reported on February 13, 2024, that subsequently became Complaint-00066, documents the justification for not performing an investigation as: “Physician determined patient had a pocket infection and made the decision to explant and device. No investigation needed.”\nii. (b)(4), reported on October 28, 2022, that subsequently became Complaint-00039, documents the “Initiate Investigation Process” option was selected but no investigation was performed and the “Review for Closure” section of the complaint records lists “no investigation needed.”\nWe reviewed your firm’s responses and conclude that they are not adequate. In the response, your firm states that CAPA 00015 was opened to capture all corrective and preventive work performed in relation to this observation. As part of CAPA 00015, your firm promised to (b)(4). Your firm also promised to (b)(4). However, the response does not address performing a retrospective review of all issues and nonconforming product reports to determine if other complaints exist and if investigations need to be performed. Several of the items promised by your firm continue to be in-progress (including but not limited to (b)(4).\n2. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR 820.90(a).\nSpecifically, your Nonconformance Material Procedure, #1707-002, does not include a provision for the determination of the need for an investigation. For example, the following two nonconformances did not include a documented investigation or evaluation:\na. (b)(4) was created on June 27, 2024, for IMD batteries that were sent to your contract manufacturer for use in production were returned due to nonconformances (bent prongs). The disposition of the batteries was recorded as being scrapped. However, there was no investigation conducted into the cause of the bent probes and the nonconformance record does not include a rationale for not investigating.\nb. (b)(4) was created on June 7, 2023, for the EXD-001 Battery Packaging Label (p\u002Fn (b)(4)) on the EXD-001 Battery, 10 Packs (p\u002Fn (b)(4)) listing an incorrect expiration date and battery lot code in finished goods inventory. Your firm reworked the nonconforming product. However, there was no investigation conducted into the cause of the incorrect labeling and the nonconformance record does not include a rationale for not investigating.\nWe reviewed your firm’s responses and conclude that they are not adequate. Your response promises to (b)(4) as well as plans to (b)(4). All activities are captured in CAPA 00017 and all work is promised by (b)(4). However, your response fails to address if a retrospective review of NCMRs will be conducted. Several of these promised actions (including CAPA 00017) remain in-progress with a tentative CAPA Effectiveness Verification planned due date of (b)(4).\n3. Failure to adequately establish and maintain procedures for validating the device design to include adequate risk analysis, as required by 21 CFR 820.30(g). Specifically, section 6.14 of your Risk Management Procedure, #1701-011, covers the information collection, information review, and actions related to the use of the Corrective and Preventive Action System and the Complaint System to monitor the device in the clinical and post-production phase to determine if reassessment of risks and\u002For assessment of new risks is necessary. Your firm failed to reassess the risk when estimated risks from a hazard differed from the actual risk observed in post-market CAPA and complaint data. For example:\na. Your firm has received three complaints of infection with the IMD portion of the Guardian System out of a total of (b)(4) IMDs implanted as of February 25, 2025. The observed rate of infection is (b)(4)%. In your device risk file, Guardian System Risk Assessment – P18, #0201-0200-001#P18, Rev B, dated November 13, 2023, the rate of infection was estimated to be (b)(4)%. The risk was not reassessed.\nb. Your firm has received 24 complaints of battery failure due to electrical short before the device reached its expected service life of 6 years, causing patients to opt for early explant and\u002For replacement. The observed rate of battery failure is (b)(4)%. In your device risk file, IMD AMSG3-E Hardware FMECA Report – P16, #0212-0201-001#P16, Rev A; dated February 24, 2015, the rate of battery failure was estimated to be (b)(4)%. Further, your firm initiated CAPA-00012 in response to the battery failures. The “Process Impacts” section of this CAPA indicates that no updates to risk management were needed. The risk was not reassessed.\nWe reviewed your firm’s responses and conclude that they are not adequate. In the response, your firm indicates that CAPA 00016 was opened to address any corrective and preventive work taken as result of the observation including to assess the risk associated with infection using current performance data against historical data and to address the need to perform risk reviews on a regularly scheduled basis to keep the risk data current by July 1, 2025. However, your firm did not indicate if you intend to review, and update as necessary, the risk file utilizing post-market data for items other than risk of infection. Several of the items promised by your firm continue to be in-progress, including but not limited to (b)(4) which has a (b)(4) planned due date of (b)(4).\n4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm failed to follow your procedure, Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, when taking corrective and preventive actions. Two examples of lack of CAPA procedure implementation are as follows:\na. Your firm failed to follow your CAPA process for a corrective action taken as a result of a consumer complaint which led to a revision made to manufacturing procedure Process Specification, PROG-004 Final Shipping Manufacturing, #0217-1200-020#P18, Rev F, dated November 19, 2024. These actions were taken outside of the CAPA system and lack a documented CAPA investigation as well as verification of implementation and effectiveness.\nb. Your firm failed to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). Specifically, section 5.9 of the Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, describes your firm’s process for establishing verification of effectiveness plans with predetermined criteria that verify if corrective and\u002For preventive actions were effective. Additionally, section 5.10 of the Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, describes the process for conducting the verification of effectiveness (VOE) phase to demonstrate effectiveness.\nReview of five CAPAs closed between January 2022 and the time of the current inspection disclosed that four CAPAs (CAPA-00007, CAPA-00008, CAPA-00010, and CAPA-00014) lacked evidence that your firm verified or validated that the action taken was effective.\nFor example, CAPA-00007, was opened as a result of the previous inspection on March 15, 2022, related to a complaint involving EXD batteries having expired shelf life. Your firm implemented several corrective actions to correct the issue which were documented utilizing the complaint record (complaint number 00013) instead of through the CAPA system. CAPA-00007 was closed on March 31, 2022, without verifying the effectiveness of the correction and preventive actions taken.\nWe reviewed your firm’s responses and conclude that they are not adequate. In this response, your firm opened CAPA 00016 to document actions taken for this observation. Your firm promises to (b)(4). For the 5 CAPAs lacking VOE plans and reports, your firm asks our Agency if (b)(4) (2021 or earlier). The decision to (b)(4) remains your firm’s decision as long as it is based on a rationale you determine to be appropriate given the 21 CFR 820.100(a)(4) and your own procedural requirement to demonstrate effectiveness of a CAPA action. You are also going to (b)(4). Your response does not address if other CAPAs will be reviewed to determine if (b)(4). Several of the items promised by your firm continue to be in-progress (including but not limited to (b)(4).\n5. Failure to validate with a high degree of assurance and approve according to established procedures, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). Specifically, your firm’s Process Validation Procedure, #1705-002, Rev E, dated October 23, 2020, and Process Qualification Procedure, #1705-001, Rev F, dated October 23, 2020, were not adequately established in that both procedures fail to address sterilization validation. Your firm’s implantable cardiac monitoring device (IMD) undergoes (b)(4) sterilization. Further, the two procedures fail to document the process of requalification and revalidation (if necessary) of the sterilization cycle.\nFor example, the (b)(4) sterilization process for your firm’s IMD was last performed in June 2022 by a 3rd party in accordance with FDA-recognized standard ANSI\u002FAAMI\u002FISO 11135:2014. Your firm has not reviewed the (b)(4) sterilization process since the 2022 requalification.\nWe reviewed your firm’s responses and conclude that they are not adequate. In the responses, you indicate that CAPA 00019 was opened as a result of the observation and that your firm promises to (b)(4). However, your responses do not address if your firm’s plans to revise your process validation procedures to include sterilization. Additionally, supporting evidence (including CAPA 00019) of these promised actions remain in progress with a CAPA Effectiveness Verification planned due date for CAPA 00019 of (b)(4).\n6. Failure to adequately establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants, as required by 21 CFR 820.50(a). Specifically, your Supplier Management Procedure (#1703-003), has not been fully implemented. For example:\na. Your firm’s Supplier Management Procedure (#1703-003) describes a process for supplier evaluation and acceptance using a supplier evaluation form. The Supplier Evaluation Form for the IMD battery supplier, (dated February 13, 2020), indicated your firm’s contract manufacturer would perform receiving inspections of these batteries and provide (b)(4) to Avertix. Your QA\u002FQC manager stated these (b)(4) were not completed.\nb. Your firm failed to adequately establish and maintain records of acceptable suppliers, contractors, and consultants, as required by 21 CFR 820.50(a)(3). Specifically, section 7.1.12 of Supplier Management Procedure, Rev K, states that “Quality Assurance is responsible for revising the Approved Supplier List with changes made based on acceptance\u002Frejection of potential suppliers\u002Fre-evaluated suppliers\u002Fdeactivated suppliers…” A software supplier used by your firm since 2023 to meet the requirements of the Medical Device Tracking regulation was not listed on your Approved Supplier List (Rev L, dated June 15, 2023).\nWe reviewed your firm’s responses and conclude that they are not adequate. In the responses, your firm promises and provided revisions to your Supplier Management Procedure (Document 1703-003) removing the requirement for (b)(4) for your contract manufacturer and to evidence of a new supplier evaluation for the software supplier utilized for medical device tracking by July 1, 2025. The responses do not indicate if other supplier evaluations will be evaluated and updated, as needed. Further, CAPA 00023 remains in progress with a CAPA Effectiveness Verification planned due date of December 1, 2025.\nMedical Device Reporting (MDR) Violations\nOur inspection also revealed that your firm’s Guardian System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 803 - Medical Device Reporting was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\n1. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\nFor example, the information included for Complaint-00066, Issue-00091, and Complaint-00039 reasonably suggests that each patient sustained an injury or illness (i.e., infection) following implantation of your firm’s Guardian System. These infections constituted serious injuries within the meaning of 21 CFR 803.3(w) because they necessitated surgical intervention (i.e., explantation) to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of information that reasonably suggests that the Guardian System may have caused or contributed to a serious injury on February 13, 2024, for Complaint-00066, on November 6, 2023, for Issue-00091, and on October 28, 2022, for Complaint-00039. As such, Complaint-00066, Issue-00091, and Complaint-00039 represent MDR reportable events, as defined in 21 CFR 803.3(o)(2)(i). However, the FDA did not receive an MDR for each referenced event until April 10, 2025, which exceeded the required 30 calendar day reporting timeframe.\nThe adequacy of your firm’s responses cannot be determined at this time. We acknowledge that the FDA received the manufacturer reports, submitted using the electronic equivalent of Form 3500A, for the referenced serious injury events after the 30 calendar day reporting timeframe had elapsed. However, although the response referenced the updated MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, as part of its correction action for the late reporting issue, a copy of the updated MDR procedure was not included.\n2. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nFor example, the information included for Complaints No. 00057, 00065, 00070, 00071, 00072, 00074, 00077, 00079, 00080, 00082, 00083, and 00086, reasonably suggests that your firm’s Guardian System malfunctioned while in use. Specifically, the device prematurely reached its end of service due to early battery depletion, meaning that it failed to meet its performance specifications or otherwise perform as intended under 21 CFR 803.3(k). Your firm initiated recall Z-1140-2025 for the referenced malfunction. A malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the Act as a result of the malfunction of the device or other similar devices. See Medical Devices; Medical Device User Facility and Manufacturer Reporting, Certification and Registration, 60 Fed. Reg. 63585 (Dec. 11, 1995) (referring to section 519(f), which has since been redesignated as section 519(g)). As such, the referenced complaints represent MDR reportable events, as defined under 21 CFR 803.3(o)(2)(ii).\nYour firm became aware of information on the following dates that reasonably suggests that the Guardian System had malfunctioned and this device or a similar device your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur: October 10, 2023, for Complaint No. 00057; February 26, 2024, for 00065; May 28, 2024, for 00070; May 14, 2024, for 00071; May 5, 2024, for 00072; May 14, 2024, for 00074; July 17, 2024, for 00077; August 29, 2024, for 00079; August 21, 2024, for 00080; November 19, 2024, for 0008; November 19, 2024, for 00083; and December 3, 2024, for 00086. Your firm submitted a report for each event using the MedWatch Online Voluntary Reporting Form. Specifically, MW5149541 (Complaint No. 00057), MW5153561 (Complaint No. 00065), MW5159171 (Complaint No. 00070), MW5159172 (Complaint No.00071), MW5159173 (Complaint No. 00072), MW5159805 (Complaint No. 00074), MW5160629 (Complaint No. 00077), MW5160632 (Complaint No. 00079), MW5160633 (Complaint No. 00080), MW5164478 (Complaint No. 00082), MW5164476 (Complaint No. 00083), and MW5164481 (Complaint No. 00086). The submission of reports using the voluntary MedWatch Online Voluntary Reporting Form does not fulfill reporting obligations arising under 21 CFR Part 803. An electronic submission of a mandatory report from a manufacturer must contain the information from the applicable blocks of Form FDA 3500A. All medical device reports must be submitted within the required timeframes. However, the FDA did not receive the corresponding MDRs until April 14, 2025, which exceeded the required 30 calendar day reporting timeframe.\nThe adequacy of your firm’s responses cannot be determined at this time. We acknowledge that the FDA received the manufacturer reports, submitted using the electronic equivalent of Form 3500A, for the referenced malfunction events based on your firm’s retrospective review on April 14, 2025, after the 30 calendar day reporting timeframe had elapsed.\nHowever, although the response referenced the updated MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, as part of its correction action for the late reporting issue, a copy of the updated MDR procedure was not included.\nIn addition, the inspection revealed that your firm failed to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, your firm presented the document titled “Medical Device Vigilance Procedures,” Document No. 1716-005, Rev. F, dated June 25, 2024, as its MDR procedure. Upon review, we conclude that the MDR procedure does not develop, maintain, and implement written MDR procedures for internal systems that provide for timely transmission of complete medical device reports to FDA, as required by 21 CFR 803.17(a)(3). Specifically, the procedure 1716-005, Rev. F does not include instructions for how your firm will comply with the 21 CFR 803.12(a) requirement to submit reports to FDA in an electronic format that FDA can process, review, and archive. As a manufacturer, you must submit reports of individual adverse events to FDA in an electronic format in accordance with 21 CFR 803.12(a) and 803.20, unless granted an exemption under 21 CFR 803.19.\nThe adequacy of your firm’s responses cannot be determined at this time. While your response included a copy of the updated Complaint Procedure, Document No.1716-002, and staff training records, it referenced an update to the MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, without including a copy. Without the referenced document, we cannot fully assess the adequacy of the response.\nCorrections and Removals Violation\nOur inspection also revealed that your firm’s Guardian System Model AMSG3‐E IMD implant devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals was promulgated under section 519 of the Act, among other provisions. Violations include, but are not limited to, the following:\nFailure to submit to the FDA within 10 working days of initiating a correction or removal a report required by 21 CFR 806.10.\nSpecifically, on September 18, 2023, Avertix Medical, Inc., delivered a letter to physicians who have patients implanted with a Model AMSG3‐E IMD manufactured during the period when a contamination issue was occurring on the battery production line. This issue led to premature battery depletion in the Guardian System implants, which can result in failure to monitor and earlier‐than‐expected implant replacement surgery. The letter recommends reducing the interval of regular follow-up visits and reinforcing the patient training. FDA determined that shorter device implant life leading to sooner than expected replacement surgery may present a risk to health. This action constitutes a medical device correction or removal initiated to reduce a risk to health posed by the device or remedy a violation of the Act caused by the device which may present a risk to health under 21 CFR 806.10(a). Accordingly, you were required to submit a Report of Correction or Removal to FDA within 10 working days of initiation, under 21 CFR 806.10(b). You submitted a Medical Device Report of Correction or Removal to FDA for this action on December 11, 2024.\nWe reviewed your firm’s responses and conclude that they are not adequate. The responses do not contain evidence that your firm’s procedures will result in compliance with the medical device correction and removal reporting requirements in 21 CFR 806. CAPA 00020 states that management failed to recognize that it needed to submit a Report of Correction or Removal within 10 working days of initiation. Your corrective action was retraining personnel in two procedures, Complaint Procedure (1716-002) and Vigilance Procedure (1716-005). You stated that your Quality Management System (QMS) procedure specifies that recalls or corrections must be reported within 10 days. However, your responses did not include a new revision of 1716-005 nor procedure 1716-004, PRODUCT RECALLS, CORRECTIONS AND REMOVALS. Procedure 1716-004 Rev F, collected in the inspection, notes that the Recall Coordinator is responsible for communicating with regulatory agencies within defined reporting times as per the Vigilance procedure. The procedure titled MEDICAL DEVICE VIGILANCE PROCEDURES, 1716-005 Rev F, collected during the inspection, does not describe Reports of Corrections or Removals, required by 21 CFR 806. Therefore, training personnel on 1716-005 will not help personnel know the timeframe for reporting a Medical Device Correction or Removal to FDA.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 711080” when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Compliance Officer at sean.moynihan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Avertix Medical, Inc.","avertix-medical-inc-711080-09032025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Favertix-medical-inc-711080-09032025","2026-10-26T08:07:59.649711+00:00","2026-03-17","711080","Timothy P. Moran","2026-08-19T04:50:38.23+00:00","2025-09-03",4,{"510k":91,"classification":92,"enforcement":93,"event":94,"event_backfill":95,"pma":96,"warning_letter":97},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]